Dataset Information

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment.

Summary

In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunotherapeutic drugs, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021)" based on current clinical studies and clinical medication experience for reference in China.

Key messages

The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients, and potential population for immunotherapy.

SUBMITTER: Yang Y

PROVIDER: S-EPMC9801175 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

Yang Yu Y Sun Juxian J Wu Mengchao M Lau Wan Yee WY Zheng Shusen S Wang Xue-Hao XH Chen Xiaoping X Fan Jia J Dong Jiahong J Cai Jianqiang J Chen Minshan M Chen Yongjun Y Cheng Zhangjun Z Dai Chaoliu C Shan Jianzhen J Du Cheng-You CY Fang Chihua C Hu Heping H Ji Zhili Z Jia Weidong W Li Gong G Li Jing J Li Jiangtao J Liu Chang C Liu Fubao F Ma Yong Y Mao Yilei Y Niu Zuoxing Z Shen Jie J Shi Jie J Shi Xuetao X Song Wenjie W Sun Hui-Chuan HC Tan Guang G Tao Ran R Wang Xiaohu X Wen Tianfu T Wu Liqun L Xia Jinglin J Xiang Bang-De BD Yan Maolin M Ying Mingang M Zhang Ling L Zhang Xuewen X Zeng Zhao Chong ZC Zhang Yubao Y Zhang Zhiwei Z Zhou Jie J Zhou Cuncai C Zhou Jun J Zhou Ledu L Zhou Xinmin X Zhu Ji J Zhu Zhenyu Z Zhang Qi Q Li Qiu Q Cheng Shuqun S

Liver cancer 20220720 6

<h4>Background</h4>Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment.<h4>Summary</h4>In recent years, immune checkpoint inhibitors have made a breakthrough in the systemic treatment of middle-advanced HCC, breaking the single therapeutic pattern of molecular-targeted agents. To better guide the clinical treatment for effective and safe use of immunothera ...[more]

PMID: 36589726

Similar Datasets

Project description:The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.

Dataset Information

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

Background

Summary

Key messages

Publications

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets